{
  "id": 13737981,
  "title": "Alnylam EVP Bryan Supran sells $398,855 in shares",
  "url": "https://urgent.news/2026/10/11/alnylam-evp-bryan-supran-sells-398-855-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-11T14:31:05.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/alnylam-evp-bryan-supran-sells-398855-in-shares-93CH-4942722"
  },
  "original_language": "en",
  "account": "Alnylam Pharmaceuticals executive Bryan Supran, the EVP, Chief Legal Officer, and Secretary, divested 1,758 shares of the company's common stock on October 2, 2026. The sale occurred at a price of $226.88 per share, generating approximately $398,855 in proceeds. Consequently, Alnylam's market value stands at $31.1 billion. According to InvestingPro analysis, the stock appears undervalued, with analysts projecting price targets ranging from $256 to $536. This transaction was executed in accordance with a mandatory \"sell-to-cover\" provision in Supran's award agreement, aimed at meeting minimum statutory tax withholding obligations upon the vesting and settlement of restricted stock units. Following this sale, Mr. Supran now holds 12,807 shares of Alnylam Pharmaceuticals common stock. InvestingPro Tips indicate that the company has been profitable in the past year, with an additional eleven tips available to subscribers. Alnylam Pharmaceuticals remains a focal point for analysts and investors. Cantor Fitzgerald maintains a Neutral rating for the company, setting a price target of $325, noting heightened interest in the upcoming data release for ALN-HTT02, an experimental treatment for Huntington's disease scheduled for October 23. H.C. Wainwright has retained a Buy rating, anticipating a $455 price target, following Alnylam's RNA interference roundtable event centered on zilebesiran, a hypertension treatment in collaboration with Roche. Truist Securities has also maintained a Buy rating, targeting $315, following a webcast discussing zilebesiran's potential to treat hypertension. The Phase 3 ZENITH CVOT trial for this treatment is currently ongoing, with top-line data expected in 2030. H.C. Wainwright reaffirmed its Buy rating after evaluating results from Ionis Pharmaceuticals' and AstraZeneca's cardiovascular treatments, highlighting Alnylam's potential for drug differentiation. These developments underscore ongoing interest and analysis surrounding Alnylam's therapeutic advancements and strategic collaborations.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Zymeworks EVP Adam Schayowitz sells $357,557 in shares",
        "url": "https://urgent.news/2026/10/11/zymeworks-evp-adam-schayowitz-sells-357-557-in-shares",
        "published": "2026-10-11T13:01:18.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}